Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/27/2015)... , July 20, 2015 ... the addition of the "Global Pressure Relief Devices ... The Global Pressure Relief Devices market to grow at ... The report, Global Pressure Relief Devices Market 2015-2019, has ... inputs from industry experts. The report covers the Americas, ...
(Date:7/27/2015)... Calif. , July 27, 2015  QT Vascular ... "Group"), a global company engaged in the design, assembly ... invasive treatment of vascular disease, has entered into an ... up to US$13.14 million convertible bond investment. This funding ... boost its growth to the next milestone. ...
(Date:7/27/2015)... July 27, 2015  Array BioPharma Inc. ... for the fourth quarter and full year ... call to discuss those results on Monday, ... Officer will lead the call. ... 464-3927Toll:(765) 507-2598Pass Code: 68380312 Webcast, including Replay ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3
... , SAN FRANCISCO, Jan. 11, 2010 Amylin Pharmaceuticals, ... priorities that will position the Company to address the dual ... by the end of the year and place the Company ... 2011. The news was presented by Daniel M. Bradbury, president ...
... , FRANKLIN LAKES, N.J., Jan. 11 ... today that it will conduct a live webcast of its first ... at 10:00 a.m. (ET). BD will issue a press release ... the conference call, along with related slides, will be accessible through ...
Cached Medicine Technology:Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 2Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 3BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... The heroin ... country, reported WCNC on July 7th. The rate for heroin usage has ... has gone down considerably, and is a less expensive alternative for those with an ...
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece ... personal side of plastic surgery and explained why people should not shy away from ... for the excesses of the few and celebrate it for the modern wonder that ...
(Date:7/27/2015)... Plains, NJ (PRWEB) , ... July 27, 2015 , ... ... tendon of an accomplished athlete. “The patient is high-end athlete, whose accomplishments include ... after 8 months of Achilles tendon pain, which was diagnosed as tendinitis. I ...
(Date:7/27/2015)... , ... July 27, 2015 , ... ... including emergency notification and mobile collaboration, announced today the ... user interface, language localization and other feature enhancements. , This software release gives ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... and in-depth research report. The report provides basic information such as calcium ... This report covers the global (US, Europe, Japan etc) industry analysis like ...
Breaking Medicine News(10 mins):Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3Health News:Send Word Now Announces Release of New User Interface for its Award-Winning Mass Notification Service 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 2Health News:Calcium Propionate Market Global Suppliers and Manufacture Analysis 3
... understanding of dopamine release from nerve cells, findings that ... treating Parkinson,s Disease. People with Parkinson,s Disease ... movement and, in extreme cases, a loss of physical ... of dopamine producing nerve cells in the brain. ...
... finds increase lowers chance of hospitalization or death ... with heart failure, high doses of the drug losartan, ... admission and death, a new study shows. , Though ... the study focused on whether dose level makes a ...
... ... expertise offers a winning combination to companies with large sales forces. , ... Chicago, IL (PRWEB) November 18, ... , knowledge and collaboration platform, and ELA Consulting Group , sales effectiveness and ...
... ... of resources to help community health officials make use of the company’s new mapping ... white paper and a free webinar, each demonstrate how Depiction can be used as ... ...
... A ... a new technique available at Houston weight loss surgery practice Texas Laparoscopic ... surgical treatment for morbid obesity. , ... (Vocus) November 18, 2009 -- Houston-based Texas Laparoscopic Consultants is a ...
... ... families learn five steps for creating joyful holidays and family celebrations. , ... (PRWEB) November 18, 2009 -- PAIRS Foundation is ... joyful holidays and family celebrations. , ,"Holidays can be a time of wonderful celebration, sharing ...
Cached Medicine News:Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 2Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 3Health News:StreetSmarts and ELA Consulting Group Forge Sales Effectiveness Partnership 4Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 2Health News:Community Health Officials Can Improve Real Time H1N1 Information Sharing with New Resources from Depiction, Inc. 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4Health News:Five Steps to Happy Family Gatherings at Holiday Time 2
The Nervous System Flash Cards product uses the time tested content and images from BryanEdwards.com and displays the necessary images to demonstrate the nervous system....
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
... Cochrane Reviews enable all those involved ... date with the very latest evidence in ... which becomes harder each year as the ... this problem by delivering the best single ...
Pocket Medicine's Cardiology Bundle includes the following 4 applications: Treatment Strategies in Cardiovascular Medicine, Treatment Strategies in Interventional Cardiology, Treatment Strategies in ...
Medicine Products: